Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 29 Note 2: Revenue Disaggregation of revenue The Group derives revenue from the transfer of goods and services over time and at a point in time in the following major product and geographical regions Asia Pacific EMEA Americas Total Consolidated - 2021 $’000s $’000s $’000s $’000s Revenue lines Reagents & consumables 21,743 3,589 1,435 26,767 Equipment sales & rental 483 837 178 1,498 Service contracts 19 - - 19 22,245 4,426 1,613 28,284 Timing of revenue recognition Goods transferred at a point in time 22,226 4,426 1,613 28,265 Services transferred over time 19 - - 19 22,245 4,426 1,613 28,284 Asia Pacific EMEA Americas Total Consolidated - 2020 $’000s $’000s $’000s $’000s Revenue lines Reagents & consumables 9,430 770 3 10,203 Equipment sales & rental 663 337 - 1,000 Service contracts 60 - - 60 10,153 1,107 3 11,263 Timing of revenue recognition Goods transferred at a point in time 10,093 1,107 3 11,203 Services transferred over time 60 - - 60 10,153 1,107 3 11,263 Note 3: Financial Reporting Segments The Group is operated under one business segment which was the research and commercialisation of identifying individual genetic signatures to identify diseases and disabilities. Major customers During the year ended 30 June 2021 there were two customers (2020: two) that each contributed over 10% of the consolidated entity’s external revenue. Financial Report